Literature DB >> 18402776

Bmx regulates LPS-induced IL-6 and VEGF production via mRNA stability in rheumatoid synovial fibroblasts.

Christine D Palmer1, Brenda E Mutch, Theresa H Page, Nicole J Horwood, Brian M J Foxwell.   

Abstract

Discordant cytokine production is characteristic of chronic inflammatory conditions like rheumatoid arthritis (RA), and anti-cytokine therapeutics are becoming routinely used to treat RA in the clinic. Fibroblasts from rheumatoid synovium have been shown to contribute to cytokine production in inflamed joints; likewise these cells also produce cytokines in response to inflammatory mediators signalling through Toll like receptors (TLRs). Tyrosine kinase activity is essential to LPS-induced cytokine production, and we have previously implicated a role for the Tec kinase, Bmx, in inflammatory cytokine production. Here we show that Bmx kinase activity in RASF is increased following LPS stimulation and that Bmx is involved in the regulation of LPS-induced IL-6 and VEGF production via mRNA stabilisation. This is an important insight into the regulation of VEGF, which is involved in a wide range of different pathologies, and may lead to more effective design of novel anti-inflammatory/angiogenic therapeutics for conditions such as RA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18402776     DOI: 10.1016/j.bbrc.2008.03.142

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Effects of Tec Tyrosine Kinase Inhibition on the Inflammatory Response of Severe Acute Pancreatitis-Associated Acute Lung Injury in Mice.

Authors:  Yiteng Meng; Shuo Sha; Jing Yang; Hongbo Ren
Journal:  Dig Dis Sci       Date:  2019-02-14       Impact factor: 3.199

2.  Mediators of Tyrosine Phosphorylation in Innate Immunity: From Host Defense to Inflammation onto Oncogenesis.

Authors:  Kamalika Nag; Anu Chaudhary
Journal:  Curr Signal Transduct Ther       Date:  2009-05

Review 3.  Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors.

Authors:  Nunzio Bottini; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

4.  Characterization of Altered Gene Expression and Histone Methylation in Peripheral Blood Mononuclear Cells Regulating Inflammation in COVID-19 Patients.

Authors:  Xiaoming Yang; Alex C Rutkovsky; Juhua Zhou; Yin Zhong; Julian Reese; Timothy Schnell; Helmut Albrecht; William B Owens; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Immunol       Date:  2022-04-04       Impact factor: 5.426

Review 5.  Recent advances in neutralizing the IL-6 pathway in arthritis.

Authors:  Charles J Malemud
Journal:  Open Access Rheumatol       Date:  2009-10-05

6.  Current understanding of tyrosine kinase BMX in inflammation and its inhibitors.

Authors:  Le Qiu; Fei Wang; Sheng Liu; Xu-Lin Chen
Journal:  Burns Trauma       Date:  2014-07-28

7.  Inhibitor of Tec kinase, LFM-A13, decreases pro-inflammatory mediators production in LPS-stimulated RAW264.7 macrophages via NF-κB pathway.

Authors:  Fei Wang; Wei Zhang; Chao Wang; Xu Fang; Hao Cheng; Sheng Liu; Xu-Lin Chen
Journal:  Oncotarget       Date:  2017-05-23

8.  Nuclear localization of the tyrosine kinase BMX mediates VEGFR2 expression.

Authors:  Tingting Liu; Yonghao Li; Hong Su; Haifeng Zhang; Dennis Jones; Huanjiao Jenny Zhou; Weidong Ji; Wang Min
Journal:  J Cell Mol Med       Date:  2019-10-23       Impact factor: 5.310

Review 9.  Cell signalling in macrophages, the principal innate immune effector cells of rheumatoid arthritis.

Authors:  Stefan K Drexler; Philip L Kong; Jeremy Wales; Brian M Foxwell
Journal:  Arthritis Res Ther       Date:  2008-10-10       Impact factor: 5.156

10.  Neutrophil Microvesicles from Healthy Control and Rheumatoid Arthritis Patients Prevent the Inflammatory Activation of Macrophages.

Authors:  Hefin I Rhys; Francesco Dell'Accio; Costantino Pitzalis; Adrian Moore; Lucy V Norling; Mauro Perretti
Journal:  EBioMedicine       Date:  2018-02-07       Impact factor: 8.143

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.